Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26077288 | 1.00 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL5791356 | 0.96 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL9843585 | 0.96 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL25467328 | 0.96 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL9537641 | 0.96 | PPM1B (0.50) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL3983080 | 0.94 | ALDH1A1 (0.49) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL3983188 | 0.94 | ALDH1A1 (0.49) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL15712143 | 0.91 | PPM1B (0.53) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL14357850 | 0.86 | PPM1B (0.46) | PPM1BPTPN1PPP1CCNPC1RAB9A | |
| SCHEMBL24879430 | 0.85 | PPM1B (0.40) | PPM1BPTPN1PPP1CCNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117136052-A | CDK inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-114599648-A | Triazole carboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599640-A | Isoxazole carboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| EP-3219711-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Glaxo Group Limited (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219711-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Glaxo Group Limited (GB) | 2017-09-20 | — | — | EP | disclosed |
| EP-2928885-B1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| EP-2928885-B1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2017-03-22 | — | — | EP | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| EP-2928885-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Glaxo Group Limited (GB) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086894-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086894-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2014-06-12 | — | — | WO | disclosed |
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | PPM1B 2811/4885PTPN1 4751/4885PPP1CC 3561/4885 |
| US-20150299121-A1 | MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | RORB, RORC, RORA | PPM1B 1937/4885PTPN1 716/4885PPP1CC 3523/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | PPM1B 2811/4885PTPN1 4751/4885PPP1CC 3561/4885 |
| US-10005731-B2 | Modulators of the retinoid-related orphan receptor gamma (ROR-gamma) for use in the treatment of autoimmune and inflammatory diseases | RORB, RORC, RORA | PPM1B 1937/4885PTPN1 716/4885PPP1CC 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.